Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

doi:10.1001/jama.2015.11904

. 2015 Nov 10;314(18):1973-5.

doi: 10.1001/jama.2015.11904.

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

Lauren B Cooper¹, Bradley G Hammill¹, Eric D Peterson¹, Bertram Pitt², Matthew L Maciejewski³, Lesley H Curtis¹, Adrian F Hernandez¹

Affiliations

¹ Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
² Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor.
³ Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Durham, North Carolina.

PMID: 26547470
PMCID: PMC4843996
DOI: 10.1001/jama.2015.11904

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

Lauren B Cooper et al. JAMA. 2015.

. 2015 Nov 10;314(18):1973-5.

doi: 10.1001/jama.2015.11904.

Authors

Lauren B Cooper¹, Bradley G Hammill¹, Eric D Peterson¹, Bertram Pitt², Matthew L Maciejewski³, Lesley H Curtis¹, Adrian F Hernandez¹

Affiliations

¹ Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
² Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor.
³ Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Durham, North Carolina.

PMID: 26547470
PMCID: PMC4843996
DOI: 10.1001/jama.2015.11904

No abstract available

PubMed Disclaimer

Cited by

Validation of Noninvasive Detection of Hyperkalemia by Artificial Intelligence-Enhanced Electrocardiography in High Acuity Settings.
Harmon DM, Liu K, Dugan J, Jentzer JC, Attia ZI, Friedman PA, Dillon JJ. Harmon DM, et al. Clin J Am Soc Nephrol. 2024 Aug 1;19(8):952-958. doi: 10.2215/CJN.0000000000000483. Epub 2024 Jun 21. Clin J Am Soc Nephrol. 2024. PMID: 39116276
Epidemiology and risk factors for hyperkalaemia in heart failure.
Grobbee DE, Filippatos G, Desai NR, Coats AJS, Pinto F, Rosano GMC, Cleland JGF, Kammerer J, de Arellano AR. Grobbee DE, et al. ESC Heart Fail. 2024 Aug;11(4):1821-1840. doi: 10.1002/ehf2.14661. Epub 2024 Mar 4. ESC Heart Fail. 2024. PMID: 38439165 Free PMC article. Review.
Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.
Carvalho PEP, Veiga TMA, Lacerda H, Tofanelli MR, Gewehr DM, Nunes MCP, Simões E Silva AC. Carvalho PEP, et al. Clin Res Cardiol. 2023 Jul;112(7):991-1002. doi: 10.1007/s00392-023-02215-2. Epub 2023 May 4. Clin Res Cardiol. 2023. PMID: 37140823
Noninvasive Screening Tool for Hyperkalemia Using a Single-Lead Electrocardiogram and Deep Learning: Development and Usability Study.
Urtnasan E, Lee JH, Moon B, Lee HY, Lee K, Youk H. Urtnasan E, et al. JMIR Med Inform. 2022 Jun 3;10(6):e34724. doi: 10.2196/34724. JMIR Med Inform. 2022. PMID: 35657658 Free PMC article.
Eplerenone: The Multifaceted Drug in Cardiovascular Pharmacology.
Pradhan A, Vohra S, Sethi R. Pradhan A, et al. J Pharm Bioallied Sci. 2020 Oct-Dec;12(4):381-390. doi: 10.4103/jpbs.JPBS_338_19. Epub 2020 Oct 8. J Pharm Bioallied Sci. 2020. PMID: 33679083 Free PMC article. Review.

See all "Cited by" articles

References

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239. - PubMed
1. Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82–82. - PMC - PubMed
1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717. - PubMed
1. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. - PubMed
1. Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097–2107. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239. - PubMed

[2] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239. - PubMed

[3] Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82–82. - PMC - PubMed

[4] Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82–82. - PMC - PubMed

[5] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717. - PubMed

[6] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717. - PubMed

[7] Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. - PubMed

[8] Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. - PubMed

[9] Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097–2107. - PubMed

[10] Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097–2107. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

Affiliations

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical